“COVID Trials Threatened by Shifting Surges” — MRCT Center Faculty Director, Dr. Barbara E. Bierer, discussed the state of clinical trials in the COVID-19 era, the need for clinical trial networks to be in place beforehand to speed broad multisite collaborations and the benefit of the COVID-19 Collaboration Platform in MedPageToday.
MRCT Center Program Director, Deborah A. Zarin contributed to STAT’s The Pharmalot View “Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results.”
Comments provided on: April 29, 2020
Comments provided to : European Commission
Diagnostic tests for COVID-19 are central to most proposed plans for relaxing physical distancing and related policies.
The following work by Deborah A. Zarin, MD MRCT Center Program Director and Joseph Lau, MD ,Professor Emeritus of Health Services, Policy and Practice, Center for Evidence Synthesis in Health, Brown University School of Public Health serves as a reminder about what we know and don’t know about these tests, how frequently they might produce inaccurate results, and how these inaccuracies might affect their utility in different potential scenarios. Read Paper >
Published on: March 20, 2020
Published in: Science
Published on: March 2, 2020
Published in: European Journal of Human Genetics
Listen to Dr. Deborah Zarin, MRCT Center Program Director of Advancing the Clinical Trial Enterprise and former director of ClinicalTrials.gov with Science Magazine journalist, Charles Piller on Science Friday discussing recent investigations on ClinicalTrials.gov reporting practices.
Science Friday episode “Drug Researchers Refuse To Follow The Law. The Government Isn’t Stopping Them.”
Science Magazine article “FDA and NIH let clinical trial sponsors keep results secret and break the law” by Charles Piller featuring Dr. Deborah Zarin.
Read Now >
Broadcast on: January 24, 2020
Podcast: Science Friday
Before any new drug comes to market, it goes through a time-consuming process. Researchers have to recruit human subjects for a clinical trial, collect all the data, and analyze the results. All of that can take years to complete, but the end result could be worth it: a drug that treats a rare disease or improves patients lives with fewer side effects.
